NCT06816615 Diagnosis and Percutaneous Treatment of Biliary Tract Diseases
| NCT ID | NCT06816615 |
| Status | Recruiting |
| Phase | — |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna |
| Condition | Gallstone |
| Study Type | INTERVENTIONAL |
| Enrollment | 24 participants |
| Start Date | 2022-10-14 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 24 participants in total. It began in 2022-10-14 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to implement and optimize the treatment of bile duct diseases in participants not eligible for endoscopic treatment using the Spyglass system, a system suitable for diagnostic and therapeutic endoscopic procedures in the pancreatic-biliary system, including the hepatic ducts. The main question it aims to answer is: \- Can the percutaneous cholangioscopic assisted technique resolve the biliary litiasis and/or perform endobiliary biopsies in less time than the traditional technique? Participants will undergo a colangioscopic-assisted treatment using the SpyGlass mini-endoscopic system at the Addomino-pelvic diagnostic and interventional radiology UOC of the Bologna University Hospital.
Eligibility Criteria
Inclusion Criteria: * Radiological diagnosis of indeterminate gallstones or stenosis of the bile ducts not eligible for endoscopic treatment and/or previous failed endoscopic treatment * Good liver function (hemoglobin, hematocrit, GOT, GPT, GGT within normal ranges) * Age over 18 * Obtaining informed consent Exclusion Criteria: * presence of severe untreatable coagulopathies
Contact & Investigator
Alberta Cappelli, MD
PRINCIPAL INVESTIGATOR
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Frequently Asked Questions
Who can join the NCT06816615 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Gallstone. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06816615 currently recruiting?
Yes, NCT06816615 is actively recruiting participants. Contact the research team at alberta.cappelli@aosp.bo.it for enrollment information.
Where is the NCT06816615 trial being conducted?
This trial is being conducted at Bologna, Italy.
Who is sponsoring the NCT06816615 clinical trial?
NCT06816615 is sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. The principal investigator is Alberta Cappelli, MD at IRCCS Azienda Ospedaliero-Universitaria di Bologna. The trial plans to enroll 24 participants.